MED10 and cancer: Considering the systemic nature of cancer, and the significant alteration observed in the global immune landscape of patients with refractory, metastatic, and/or recurrent cancer, our data showing that elevated MED10 expression is associated with low levels of tumor-infiltrating CD8+ T cells and high MDSC and Treg levels is of therapeutic relevance, especially as the peripheral immune system is an essential driver of effective innate and treatment-induced anticancer immune responses (31).